Stoop et al. used quantitative mass spectrometry to profile the cerebrospinal fluid proteome of multiple sclerosis patients where a panel of candidate biomarkers were identified such as chromogranin A, clusterin, complement C3 and complement C4B.[8]. This evidence concerns the gene C3 and multiple sclerosis.